Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02970318
Previous Study | Return to List | Next Study

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02970318
Recruitment Status : Active, not recruiting
First Posted : November 22, 2016
Last Update Posted : March 15, 2019
Sponsor:
Information provided by (Responsible Party):
Acerta Pharma BV

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : January 2020
  Estimated Study Completion Date : March 2020